Abstract: Subjecting 1,4-bis-[(pyrrolin-3-onyl)methylamino]-2-butyne to ultraviolet irradiation effects rearrangement in greater than 80% yield to 1,4-bis-[(isocyanatocyclopropyl)methylamino]-2-butyne. The diisocyanate is useful in the synthesis of polyurethanes and polyureas and also for the in situ photochemical generation of a cross-linking agent for polyurethanes and structurally related polymers.

Abstract: New and useful intermediate nucleotides bound to an inorganic polymer support, including the preparation thereof, and processes for the conversion to oligonucleotides which are especially useful for the synthesis of polynucleotides, particularly ribonucleic (RNA) and deoxyribonucleic acids (DNA).

Abstract: Amorphous chalcogenide films substantially free from particulate and microstructure are formed on a substrate from solution. The solution contains a glass-forming chalcogenide compound dissolved in a non-aqueous vaporizable solvent, such as a low molecular weight amine, and is substantially free from particulate or crystallizable material. Film formation is effected by coating the solution onto the substrate in a non-vacuumized environment, and thereafter evaporating the solvent from the coating. The procedure is particularly useful in forming amorphous chalcogenide resists for photolithographic applications.

Abstract: Total or fractional precipitation of proteins from salt-containing proteinaceous solution or suspension mixtures is induced or enhanced by subjecting the proteinaceous mixture to a desalting treatment, for example, by electrodialysis. In one aspect of the invention, the desalting treatment is used in conjunction with the addition of heavy metal ions to the proteinaceous mixture to provide a synergistic effect on the precipitation of the protein fraction. In another aspect of the invention, the desalting treatment, either with or without the heavy metal ion addition, is employed as an integral part of a selective plasmapheresis procedure for the removal or recovery of one or more selected plasma proteins from blood plasma.

Abstract: Cyclic analogues of the tridecapeptide hormone, .alpha.-melanotropin. (.alpha.-melanocyte stimulating hormone, .alpha.-MSH), wherein a physiologically stable intramolecular interaction exists (1) between the amino acid residue at position 4 and an amino acid residue at position 10 or 11, and/or (2) between the amino acid residue at position 5 and an amino acid residue at position 10 or 11. Preferred analogues, e.g., [half-Cys.sup.4, half-Cys.sup.10 ]-.alpha.-MSH display greatly increased in vitro potency, prolongation, and resistance to enzymatic degradation.

Abstract: A synthetic polymeric ice nucleation inhibitor is employed for protecting light frost-sensitive plants against frost injury by inhibiting the ice-nucleating activity of the ice-nucleating bacteria normally present on the plants, and thereby reducing the temperature at which frost injury occurs. The inhibitor is applied to the plants in the form of a solution of a synthetic polymer having covalently bound to its main backbone chain both pendant hydrophobic groups and pendant hydrophilic groups. The ratio of and average intermolecular spacing between the hydrophobic groups and the hydrophilic groups in the polymer, and the molecular weight of the polymer, are selected so that in combination they provide the polymer with a limited room temperature water solubility within the range of from about 1 .mu.g/ml to about 100 mg/ml.

Abstract: F(ab').sub.2 or Fab fragments of antibodies to: (a) human chorionic gonadotropin (hCG), hCG alpha subunit, hCG beta subunit, or an hCG-like material; or (b) other tumor specific or tumor associated molecules, to include carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), human melanoma associated antigens, human sarcoma associated antigens or other antigens, are radiolabeled with technetium-99m (Tc-99m). When the F(ab').sub.2 or Fab fragments of antibody to such tumor associated antigens are injected intravenously into a patient, the radiolabeled composition accumulates at tumor sites. The accumulation of the cancer seeking radiopharmaceutical at tumor sites permits detection by external gamma scintigraphy. Thus, the composition is useful in the monitoring, localization and detection of cancer in the body.In an alternative composition, a double antibody approach to tumor localization using radiolabeled F(ab').sub.2 or Fab fragments is utilized.

Abstract: The disclosed invention employs an optical heterodyne technique that depends upon coherent detection of phase modulated light from individual particles, and does not depend on measurement of light scattered at a specific angle from particles. A collimated coherent beam of light is generated and separated into a subject beam and a reference beam. The subject beam is focused at the inspection region and light is gathered from the inspection region. The gathered light and the reference beam are combined and a photodetector is responsive to the combined light for producing an electrical signal representative of the combined light. The phase shift of light scattered from an individual particle passing through the inspection region is then determined by measuring the power in the phase modulated sidebands of the electrical signal. The phase shift is indicative of the size of the particle passing through the inspection region.

Abstract: Antibodies to human carcinoembryonic antigen (CEA), human alphafetoprotein (AFP) and/or to other anti-human tumor associated antigens (TAA) labeled with technetium-99m (Tc-99m) are administered to a human after the human has been administered anti-CEA, anti-AFP and/or other anti-TAAs, such as human melanoma-associated antigen, human neuroblastoma-associated antigen, human breast cancer-associated antigen, human ovary-associated antigen, human sarcoma-associated antigen, etc. The biodistribution of the labeled product composition accumulates at cancer sites, e.g., tumors that produce or express TAA, due to the affinity that the antibody has for the given tumor antigen. The accumulation at the tumor site(s) of a suitable amount of Tc-99m associated with the antibody allows detection via external scintigraphy and other means. Detection of the Tc-99m antibody composition by external scintigraphy permits localization and detection of tumors in vivo via a semi-noninvasive technique.

Abstract: A non-invasive birth control device in the form of a custom-formed, valved cervical cap is disclosed. The cervical cap comprises a cup-shaped elastomeric shell substantially complementary with contiguous surface of portio vaginalis cervicis when in contact therewith and having an aperture at the apex of the shell. The aperture is covered by an elastomeric web secured to the shell and defines, together with the shell, a one-way valve having a discharge port offset from the aperture. The cervical cap can be fabricated from a specially designed blank of a thermoplastic elastomeric material using a replica of cervix uteri as a mold.

Abstract: A chromatographic procedure for the purification of a proteolytic procoagulant enzyme from extracts of human and animal tumors. The extracts are sequentially contacted with a first benzamide affinity chromatographic resin, an agarose filtration gel, a second benzamide affinity chromatographic resin and a phenyl-sepharose hydrophobic chromatographic resin. The resulting enzyme is capable of producing anti-procoagulant antibody which, which used in an immunoassay, is diagnostic for malignancy.

Abstract: Compounds of the formula, I, ##STR1## wherein: Y is hydrogen or lower alkyl; and X is a thiazolamino radical, a furfurylamino radical or a radical of the formula, ##STR2## in which R, R.sup.1, and R.sup.2 are the same or different and selected from the group consisting of hydrogen and lower alkyl, and R.sup.3 is selected from the group consisting of lower alkenyl, halo-lower alkenyl, lower alkynyl, lower akloxycarbonyl, thienyl, formamyl, tetrahydrofuryl and benzene sulfonamide.Also disclosed are novel methods for treatment of neoplastic disease states in animals, which methods comprise administering a therapeutically effective amount of a compound of the formula, Ia, ##STR3## wherein: Y is hydrogen or lower alkyl; and Z is a thiazolamino radical, a furfurylamino radical, a cyclopropylamino radical, a pyridylamino radical, or a radical of the formula, ##STR4## in which R.sup.4, R.sup.5, and R.sup.6 are the same or different and selected from the group consisting of hydrogen and lower alkyl, and R.sup.

Abstract: Analogues of the tridecapeptide hormone, .alpha.-melanotropin (a-melanocyte stimulating hormone, .alpha.-MSH) of the formula:Ac-Ser.sup.1 -Tyr.sup.2 -Ser.sup.3 -Y.sup.4 -Glu.sup.5 -His.sup.6 -X.sup.7 -Arg.sup.8 -Trp.sup.9 -Gly.sup.10 -Lys.sup.11 -Pro.sup.12 -Val.sup.13 -NH.sub.2wherein X and Y are amino acid residues and X is in a D-isomeric configuration. Preferred analogues, e.g. [Nle.sup.4, D-Phe.sup.7 ]-.alpha.-MSH, display increased in vitro and in vivo potency, prolongation and serum stability characteristics and may be covalently bonded to other elements or compounds (e.g., radioisotopes of iodine) without significant loss of biological activity.

Abstract: New and useful intermediate nucleotides bound to an inorganic polymer support, including the preparation thereof, and processes for the conversion to oligonucleotides which are especially useful for the synthesis of polynucleotides, particularly ribonucleic (RNA) and deoxyribonucleic acids (DNA).

Abstract: Vitamin B.sub.12 (cobalamin) and/or folate (folic acid) assay techniques can be simplified, by eliminating the step of heating or boiling the to-be-tested sample prior to its assay. This is accomplished by utilizing compositions and procedures:(1) which substantially completely liberate all vitamin B.sub.12 and/or folate from endogenous binding protein without heating or boiling;(2) which substantially completely destroy all endogenous binding protein which is present in the to-be-assayed sample, and which may bind natural and radioactive vitamin B.sub.12 or folate both due to its liberation from vitamin B.sub.12 or folate in the original sample or due to its unbound presence in the original sample;(3) which substantially completely inhibit or block any undestroyed endogenous binding protein; and(4) which substantially completely inhibit or destroy any intrinsic factor-blocking antibodies which may be present in the to-be-assayed sample.

Abstract: A non-invasive birth control device in the form of a custom-formed, valved cervical cap is disclosed. The cervical cap comprises a cup-shaped elastomeric shell substantially complementary with contiguous surface of portio vaginalis cervicis when in contact therewith, having an aperture at the apex of the shell, and a depending skirt that is thinner than said shell and is provided with a plurality of spaced slits. The aperture is covered by an elastomeric web secured to the shell and defines, together with the shell, a one-way valve means having a discharge port offset from the aperture. The cervical cap can be fabricated from a specially designed blank of a thermoplastic elastomeric material using a replica of cervix uteri as a mold.

Abstract: The reticulocyte content present in a specimen of red blood cells is quantitatively measured based upon the selective immunoreactivity of the reticulocyte portion of the specimen with a reticulocyte-specific antibody which is immunoreactive with proteinaceous material associated with reticulocytes but not associated with mature red blood cells. Such immunoreactive proteinaceous material may be transferrin, transferrin receptor, transcobalamin II, or transcobalamin II receptor. Various procedures are described for quantitating such selective immunoreactivity, including fluorescent and radioactive detection techniques employing direct or indirect fluorescent or radioactive labeling of the reticulocyte-specific antibody.

Abstract: A new series of technetium chelating agents based on amide and mercaptide donor groups is described, exemplified by 2,3-bis(mercaptoacetamido)propanoic acid. Chelation of Tc-99 m with 2,3-bis(mercaptoacetamido)propanoic acid resulted in two components that were separable by high-performance liquid chromatography. The component that eluted first demonstrated high specificity for renal excretion with over 90% in the urine in rabbits at 35 minutes and 87% in the urine of mice at 2 hours and 1.6% or less in the intestines of mice. Excretion was rapid with the first component equal to or greater than I-131 Hippuran in the urine of rabbits at all times. The second or latter component demonstrated comparable specificity, but slower renal excretion kinetics. 2,3-Bis-(mercaptoacetamido)succinic acid forms similar chelates with technetium which are also useful as radiopharmaceuticals for the renal systems of mammals.

Abstract: Heterocatalyst systems wherein a metal complex is reacted with an --OH group that is in a zeolite or molecular sieve pore, aperture, channel, cavity or cage; improved carbonylation and hydrogenation catalysts, as well as catalysts for Fischer-Tropsch reactions are disclosed; rhodium reaction product with an --OH group within a type 13X or 13Y zeolite cage is a typical catalyst.

Abstract: A method for recovering superalloy scrap is disclosed. The method involves oxidizing superalloy scrap in an aqueous acidic medium. The aqueous acidic medium has an oxidation potential sufficient to oxidize nonferrous additive superalloy elements to insoluble oxides thereof and to oxidize major superalloy constituents to aqueously soluble species. The insoluble solids from the aqueous solution are separated when the aqueous solution is extracted with an aqueously substantially insoluble tertiary amine to form an organic phase and an aqueous phase. The aqueous phase contains essentially nickel and chromium values. The organic phase is sequentially extracted with aqueous solutions which selectively solubilize individual metal value species to form individual aqueous solutions having substantially single metal value species therein. The metal value species solutions are processed to obtain substantially pure metals.